- Home
- CDTG vs AKTX Comparison
CDTG vs AKTX Comparison
Compare CDTG & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- AKTX
- Stock Information
- Founded
- CDTG 2012
- AKTX N/A
- Country
- CDTG China
- AKTX United States
- Employees
- CDTG N/A
- AKTX N/A
- Industry
- CDTG
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- CDTG
- AKTX Health Care
- Exchange
- CDTG NYSE
- AKTX Nasdaq
- Market Cap
- CDTG 24.5M
- AKTX 41.8M
- IPO Year
- CDTG 2024
- AKTX N/A
- Fundamental
- Price
- CDTG N/A
- AKTX $1.17
- Analyst Decision
- CDTG
- AKTX
- Analyst Count
- CDTG 0
- AKTX 0
- Target Price
- CDTG N/A
- AKTX N/A
- AVG Volume (30 Days)
- CDTG 746.4K
- AKTX 27.5K
- Earning Date
- CDTG 05-15-2025
- AKTX 08-18-2025
- Dividend Yield
- CDTG N/A
- AKTX N/A
- EPS Growth
- CDTG N/A
- AKTX N/A
- EPS
- CDTG 0.14
- AKTX N/A
- Revenue
- CDTG $29,765,205.00
- AKTX N/A
- Revenue This Year
- CDTG N/A
- AKTX N/A
- Revenue Next Year
- CDTG N/A
- AKTX N/A
- P/E Ratio
- CDTG $4.90
- AKTX N/A
- Revenue Growth
- CDTG N/A
- AKTX N/A
- 52 Week Low
- CDTG $0.52
- AKTX $0.85
- 52 Week High
- CDTG $4.64
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- AKTX 45.49
- Support Level
- CDTG N/A
- AKTX $1.10
- Resistance Level
- CDTG N/A
- AKTX $1.18
- Average True Range (ATR)
- CDTG 0.00
- AKTX 0.07
- MACD
- CDTG 0.00
- AKTX 0.00
- Stochastic Oscillator
- CDTG 0.00
- AKTX 53.25
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.